GlassScriptPhysician profile
Joseph E Shankland
NPI 1215262431
$11,412.29
in general payments reported to CMS, 2019-2025
36 companies · $1,543 in 2025
The $1,543 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,610 · 2022: $3,174 · 2023: $2,633 · 2024: $2,452 · 2025: $1,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,175 · Travel and Lodging: $395 · Education: $59.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,174.96 |
| Travel and Lodging | $394.56 |
| Education | $59.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,887.11 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Abbvie INC. | $2,238.34 | 2021-2025 | |
| Mml US, INC. | $1,231.88 | 2022 | |
| Saluda Medical Americas, INC. | $856.35 | 2024-2025 | Evoke |
| Abbott Laboratories | $570.03 | 2021-2025 | Eterna, Proclaim |
| Tersera Therapeutics LLC | $416.06 | 2021-2025 | Prialt |
| Scilex Pharmaceuticals INC. | $225.20 | 2021-2023 | Ztlido |
| Allergan, INC. | $198.01 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.73 | 2021-2024 | Relistor |
| Amgen INC. | $173.93 | 2021-2022 | |
| Painteq LLC | $173.50 | 2023 | Painteq |
| Lundbeck LLC | $132.59 | 2022-2025 | Vyepti |
| Averitas Pharma INC. | $114.09 | 2023-2024 | Qutenza |
| Boston Scientific Corporation | $113.49 | 2021-2025 | Varithena Administration Pack |
| Grt US Holding, INC. | $111.93 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $111.08 | 2021 | |
| Pfizer INC. | $102.34 | 2025 | |
| Almatica Pharma LLC | $71.48 | 2021 | |
| Redhill Biopharma INC. | $58.53 | 2021 | |
| Fidia Pharma USA INC. | $58.08 | 2022-2024 | Triluron, Hyalgan, Hymovis |
| Revance Therapeutics, INC. | $55.47 | 2024 | Daxxify |
| Lilly USA, LLC | $49.83 | 2022-2025 | Mounjaro, Zepbound |
| Merz Pharmaceuticals, LLC | $37.91 | 2023 | Xeomin |
| Novartis Pharmaceuticals Corporation | $37.52 | 2021 | |
| Nevro Corp. | $25.51 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.39 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.32 | 2022 | |
| Si-Bone, INC. | $19.13 | 2025 | |
| Uswm, LLC | $18.91 | 2021 | |
| Relievant Medsystems, INC. | $18.81 | 2023 | Intracept |
| Azurity Pharmaceuticals, INC. | $16.33 | 2025 | Horizant |
| Vertex Pharmaceuticals Incorporated | $15.51 | 2025 | |
| Depuy Synthes Sales INC. | $14.33 | 2023 | Orthovisc, Monovisc |
| Globus Medical, INC. | $14.08 | 2025 | Senza |
| Pacira Therapeutics, INC. | $13.05 | 2021 | |
| Bioventus LLC | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Shankland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.